by Nate Pile, editor Nate's Notes

MannKind (MNKD) has continued to rally; after following the biotech sector for almost 25 years now, I can tell you that I find the move incredibly encouraging for the simple reason that stocks with histories like MannKind’s rarely rally like this unless “someone knows something.”

MannKind is a development stage drug company working on a form of inhalable insulin (along with an associated delivery system).

The stock has popped dramatically over the past couple of months, though without any official news releases from the company to explain the move, your guess as to what’s going on is as good as mine.

However, after following the biotech sector for just few months shy of 25 years now, I believe the odds suggest (but do not guarantee!), that someone, somewhere along the way, has figured out that the clinical trials currently underway regarding Afrezza are generating data that is “good” rather than “bad”.

And given how large the short position has become in this stock, they know that it is ripe for a short squeeze of pretty epic proportions.

I want to remind you that just because I and the company’s Founder and CEO, billionaire Alfred Mann, believe the data collected thus far on Afrezza is likely to warrant an approval from the FDA, it does not mean the FDA will agree with us... and thus the story remains highly speculative. MNKD is considered a strong buy under $3 and a buy under $5.

http://www.thestockadvisors.com/Side-Notes/MannKind-Good-news-coming.html